Headline:
"Duke to host private meeting with payers and biopharma on how to pay for Alzheimer's drugs"
Endpoints reports on July 2, 2021, that "at the request of the FDA" the Duke-Margolis Center for Health Policy will hold a "closed door meeting" which will "convene public and private payers, clinicians, academics, patient groups, and industry" to discuss "coverage and evidence challenges" for beta-amyloid Alzheimer drugs as a class. Article here.
______
It's unusual for FDA to go very far in convening meetings on "coverage" and they usually take themselves to be their own gold standard for "evidence."
